ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Other Events
Item 8.01 Other Events

On April 25, 2017, Adverum Biotechnologies, Inc. (the “Company”) received a letter from the NASDAQ Stock Market confirming that, as a result of the appointment of Richard N. Spivey, Pharm.D., Ph.D. to the Company’s board of directors and audit committee, the Company has regained compliance with NASDAQ Listing Rule 5605(b)(1), which requires that the majority of the board be composed of independent directors, and NASDAQ Listing Rule 5605(c)(2), which requires that the audit committee of the board be comprised of at least three directors who meet certain independence and other requirements.

About ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Recent Trading Information

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) closed its last trading session up +0.15 at 2.80 with 229,028 shares trading hands.